Published in J Control Release on April 23, 2012
DNA Methylation and BMI: Investigating Identified Methylation Sites at HIF3A in a Causal Framework. Diabetes (2016) 0.90
Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application. J Control Release (2013) 0.87
PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study. Pharm Res (2015) 0.76
Silencing CCR2 in Macrophages Alleviates Adipose Tissue Inflammation and the Associated Metabolic Syndrome in Dietary Obese Mice. Mol Ther Nucleic Acids (2016) 0.75
A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem (1957) 173.99
A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol (1957) 21.03
Obesity. Lancet (2005) 17.67
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 13.94
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 13.76
Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med (1997) 6.86
Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes (2007) 6.81
Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol (1990) 5.81
Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A (2002) 4.77
Adipogenesis in obesity requires close interplay between differentiating adipocytes, stromal cells, and blood vessels. Diabetes (2007) 3.87
Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol (2003) 3.27
Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release (2005) 2.74
Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat Rev Drug Discov (2010) 2.14
Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev (2004) 2.12
Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci U S A (2001) 2.11
Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes (2006) 1.94
Efficient gene transfer by histidylated polylysine/pDNA complexes. Bioconjug Chem (1999) 1.76
Relation between age of onset of obesity and size and number of adipose cells. Br Med J (1972) 1.76
Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab (2004) 1.70
Angiogenesis--a new target for future therapy. Vascul Pharmacol (2006) 1.65
Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology (2005) 1.62
Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res (2008) 1.49
Angiogenesis and obesity. Cardiovasc Res (2007) 1.49
Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond) (2007) 1.45
Peptide-mediated gene delivery: influence of peptide structure on gene expression. Bioconjug Chem (1997) 1.40
Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today (2008) 1.37
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24
Adipose tissue-specific inhibition of hypoxia-inducible factor 1{alpha} induces obesity and glucose intolerance by impeding energy expenditure in mice. J Biol Chem (2010) 1.20
Targeted delivery systems for oligonucleotide therapeutics. AAPS J (2009) 1.19
Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J (2005) 1.10
Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. J Control Release (2008) 1.07
Antisense delivery using protamine-oligonucleotide particles. Nucleic Acids Res (2000) 1.05
Polymersome delivery of siRNA and antisense oligonucleotides. J Control Release (2008) 1.04
Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J Control Release (2007) 0.99
Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res (2004) 0.99
Synthetic skin-permeable proteins enabling needleless immunization. Angew Chem Int Ed Engl (2010) 0.90
Targeting delivery oligonucleotide into macrophages by cationic polysaccharide from Bletilla striata successfully inhibited the expression of TNF-alpha. J Control Release (2008) 0.88
Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice. Am J Physiol Endocrinol Metab (2008) 0.86
Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation. J Control Release (2004) 0.84
Antisense-based cancer therapeutics: are we there yet? Expert Opin Emerg Drugs (2006) 0.84
Delivery of RNAi reagents in murine models of obesity and diabetes. J RNAi Gene Silencing (2006) 0.83
Specific down regulation of 3T3-L1 adipocyte differentiation by cell-permeable antisense HIF1alpha-oligonucleotide. J Control Release (2010) 0.81
Targeting different signaling pathways with antisense oligonucleotides combination for cancer therapy. Curr Pharm Des (2007) 0.79
RNAi-mediated gene silencing of vascular endothelial growth factor inhibits growth of colorectal cancer. Cancer Biother Radiopharm (2007) 0.78
Antisense oligonucleotide therapy in diabetic retinopathy. J Diabetes Sci Technol (2009) 0.78
Antisense inhibition of S6 kinase 1 produces improved glucose tolerance and is well tolerated for 4 weeks of treatment in rats. Pharmacology (2010) 0.77
Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials (2007) 3.12
Cancer theranostics: the rise of targeted magnetic nanoparticles. Trends Biotechnol (2011) 1.60
Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials (2010) 1.42
Functional enhancement of beta cells in transplanted pancreatic islets by secretion signal peptide-linked exendin-4 gene transduction. J Control Release (2012) 1.41
Targeting prion-like protein doppel selectively suppresses tumor angiogenesis. J Clin Invest (2016) 1.39
Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting. Biomaterials (2010) 1.33
Glioma selectivity of magnetically targeted nanoparticles: a role of abnormal tumor hydrodynamics. J Control Release (2007) 1.29
Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci (2010) 1.15
Comparison of electron spin resonance spectroscopy and inductively-coupled plasma optical emission spectroscopy for biodistribution analysis of iron-oxide nanoparticles. Mol Pharm (2010) 1.12
Simvastatin maintains osteoblastic viability while promoting differentiation by partially regulating the expressions of estrogen receptors α. J Surg Res (2011) 1.11
Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J (2005) 1.10
Re: Effect of non-surgical periodontal therapy on serum ferritin levels: an interventional study. Chakraborty S, Tewari S, Sharma RK, Narula SC. (J Periodontol 2014;85:688 to 696.). J Periodontol (2015) 1.07
Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles. Biomaterials (2011) 1.05
Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials (2011) 1.04
Comparative study of photosensitizer loaded and conjugated glycol chitosan nanoparticles for cancer therapy. J Control Release (2011) 1.04
Tumor-homing poly-siRNA/glycol chitosan self-cross-linked nanoparticles for systemic siRNA delivery in cancer treatment. Angew Chem Int Ed Engl (2012) 1.04
Substantiating in vivo magnetic brain tumor targeting of cationic iron oxide nanocarriers via adsorptive surface masking. Biomaterials (2009) 1.02
Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. Bioorg Med Chem Lett (2005) 1.01
Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography. J Control Release (2011) 1.01
Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Adv Drug Deliv Rev (2013) 0.97
Highly poly(ethylene) glycolylated islets improve long-term islet allograft survival without immunosuppressive medication. Tissue Eng (2007) 0.97
Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug Chem (2005) 0.97
Functional and histological evaluation of transplanted pancreatic islets immunoprotected by PEGylation and cyclosporine for 1 year. Biomaterials (2006) 0.96
Effect of frequent laser irradiation on orthodontic pain. A single-blind randomized clinical trial. Angle Orthod (2012) 0.95
Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers. Biomaterials (2011) 0.95
In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. Biomaterials (2007) 0.94
The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials (2009) 0.94
Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J Control Release (2006) 0.94
Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study. J Gene Med (2003) 0.94
MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin. Eur J Pharm Biopharm (2007) 0.94
Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem Biophys Res Commun (2005) 0.93
L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). J Control Release (2009) 0.93
Gum arabic-coated magnetic nanoparticles for potential application in simultaneous magnetic targeting and tumor imaging. AAPS J (2009) 0.93
TAT-modified nanosilver for combating multidrug-resistant cancer. Biomaterials (2012) 0.92
Immune reactions of lymphocytes and macrophages against PEG-grafted pancreatic islets. Biomaterials (2004) 0.92
A combined theoretical and in vitro modeling approach for predicting the magnetic capture and retention of magnetic nanoparticles in vivo. J Control Release (2011) 0.92
The artificial peroxidase activity of magnetic iron oxide nanoparticles and its application to glucose detection. Biomaterials (2009) 0.92
Synthetic skin-permeable proteins enabling needleless immunization. Angew Chem Int Ed Engl (2010) 0.90
Cell-penetrating peptides: achievements and challenges in application for cancer treatment. J Biomed Mater Res A (2013) 0.90
In vitro assessment of a novel polyrotaxane-based drug delivery system integrated with a cell-penetrating peptide. J Control Release (2007) 0.90
The minimal functional sequence of protamine. Biochem Biophys Res Commun (2005) 0.90
The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials (2009) 0.90
The magnetophoretic mobility and superparamagnetism of core-shell iron oxide nanoparticles with dual targeting and imaging functionality. Biomaterials (2010) 0.89
Magnetic nanoparticles for tumor imaging and therapy: a so-called theranostic system. Pharm Res (2013) 0.88
PEGylation of bacterial cocaine esterase for protection against protease digestion and immunogenicity. J Control Release (2009) 0.88
Injectable microparticle-gel system for prolonged and localized lidocaine release. I. In vitro characterization. J Biomed Mater Res A (2004) 0.87
PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation. J Control Release (2008) 0.87
Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics. Bioconjug Chem (2011) 0.87
The short-term effects on restenosis and thrombosis of echinomycin-eluting stents topcoated with a hydrophobic heparin-containing polymer. Biomaterials (2006) 0.87
Cell-penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy. Int J Cancer (2011) 0.87
Oral drug delivery systems using chemical conjugates or physical complexes. Adv Drug Deliv Rev (2012) 0.87
Preparation and characterization of self-assembled nanoparticles of heparin-deoxycholic acid conjugates. Langmuir (2004) 0.87
Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J Control Release (2009) 0.87
Optimization of monomethoxy-polyethylene glycol grafting on the pancreatic islet capsules. J Biomed Mater Res (2002) 0.86
Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.86
A new strategy toward improving immunoprotection in cell therapy for diabetes mellitus: long-functioning PEGylated islets in vivo. Tissue Eng (2006) 0.86
A combination therapy of PEGylation and immunosuppressive agent for successful islet transplantation. J Control Release (2005) 0.86
The effect of cellular retinoic acid binding protein-I expression on the CYP26-mediated catabolism of all-trans retinoic acid and cell proliferation in head and neck squamous cell carcinoma. Metabolism (2004) 0.86
Co-administration of protein drugs with gold nanoparticles to enable percutaneous delivery. Biomaterials (2010) 0.85
The ATTEMPTS delivery systems for macromolecular drugs. Expert Opin Drug Deliv (2008) 0.85
Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis. Clin Cancer Res (2008) 0.85
Preparation and characterization of reconstructed small intestinal brush border membranes for surface plasmon resonance analysis. Pharm Res (2004) 0.85
Enhancement of blood compatibility of poly(urethane) substrates by mussel-inspired adhesive heparin coating. Bioconjug Chem (2011) 0.85
Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects. Bioconjug Chem (2012) 0.85
Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth. Pharm Res (2008) 0.85
Associations Between the Periodontal Disease in Women Before Menopause and Menstrual Cycle Irregularity: The 2010-2012 Korea National Health and Nutrition Examination Survey. Medicine (Baltimore) (2016) 0.85
Size-tunable synthesis of stable superparamagnetic iron oxide nanoparticles for potential biomedical applications. J Biomed Mater Res A (2010) 0.84
PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting. J Control Release (2012) 0.84
Paclitaxel loaded nano-aggregates based on pH sensitive polyaspartamide amphiphilic graft copolymers. Int J Pharm (2011) 0.84
Chemoprevention of 4-NQO-induced oral carcinogenesis by co-administration of all-trans retinoic acid loaded microspheres and celecoxib. J Control Release (2005) 0.83
Effect of polyethylene glycol grafted onto islet capsules on prevention of splenocyte and cytokine attacks. J Biomater Sci Polym Ed (2004) 0.83
Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy. J Biomed Mater Res A (2009) 0.83
Intradiscal injection of simvastatin retards progression of intervertebral disc degeneration induced by stab injury. Arthritis Res Ther (2009) 0.83
Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma. Mol Pharm (2015) 0.83
Injectable microparticle-gel system for prolonged and localized lidocaine release. II. In vivo anesthetic effects. J Biomed Mater Res A (2004) 0.83